Literature DB >> 11796469

Human recombinant activated protein C in meningococcal sepsis.

Gregory Wcisel1, David Joyce, Arna Gudmundsdottir, D Michael Shasby.   

Abstract

A 19-year-old woman presented with purpura fulminans and septic shock; subsequently, progressive coagulopathy, widespread purpura fulminans associated with meningococcemia, severe shock, respiratory, and renal failure developed. This clinical course was associated with depletion of functional protein C levels to < 5%. We describe her clinical course and therapy with human recombinant activated protein C.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11796469     DOI: 10.1378/chest.121.1.292

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  4 in total

1.  Drotrecogin alfa (activated) for the treatment of meningococcal purpura fulminans.

Authors:  Esther B Bachli; Stephan R Vavricka; Roland B Walter; Monika I Leschinger; Marco Maggiorini
Journal:  Intensive Care Med       Date:  2003-01-15       Impact factor: 17.440

2.  Comment on "Early treatment with activated protein C for meningococcal septic shock: case report and literature review" by Hasin et al.

Authors:  Gareth L Thomas; Peter Clark
Journal:  Intensive Care Med       Date:  2005-11-10       Impact factor: 17.440

3.  Early treatment with activated protein C for meningococcal septic shock: case report and literature review.

Authors:  Tal Hasin; David Leibowitz; David Rot; Yoram Weiss; Tova Chajek-Shaul; Ran Nir-Paz
Journal:  Intensive Care Med       Date:  2005-05-20       Impact factor: 17.440

4.  Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies.

Authors:  Jean-Louis Vincent; Simon Nadel; Demetrios J Kutsogiannis; R T Noel Gibney; S Betty Yan; Virginia L Wyss; Joan E Bailey; Carol L Mitchell; Samiha Sarwat; Stephen M Shinall; Jonathan M Janes
Journal:  Crit Care       Date:  2005-05-17       Impact factor: 9.097

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.